论文部分内容阅读
为了评价雌激素受体（Ｅｓｔｒｏｇｅｎ Ｒｅｃｅｐｔｏｒ，ＥＲ）、孕激素受体（ＰｒｏｇｅｓｔｅｒｏｎｅＲｅｃｅｐｔｏｒ ＰＲ）、雄激素受体（Ａｎｄｒｏｇｅｎ Ｒｅｃｅｐｔｏｒ，ＡＲ）和癌基因（Ｏｎｃｏｇｅｎｅ）Ｃ－ｅｒｂＢ－２Ｏｎｃｏｐｒｏｔｅｉｎ（Ｃ－ｅｒｂＢ－２），抑癌基因（Ｔｕｍ ｏｒ Ｓｕｐｐｒｅｓｓｏｒ Ｇｅｎｅｓ） ｐ５３ 蛋白（ｐ５３）和ｐ１６蛋白（ｐ１６）在乳腺癌发生发展中的作用，以及上述蛋白检测对诊断与治疗的意义。用免疫组化Ｓ－ Ｐ法检测６ 种蛋白在６２ 例乳腺癌和１０ 例乳腺良性病变中的表达。结果ＥＲ、ＰＲ、ＡＲ、Ｃ－ｅｒｂＢ－２、ｐ１６、ｐ５３ 在乳腺癌中的表达率分别为 ８５．５％ 、７４．２％ 、２２．６％ 、７４．２％ 、９０．３％ 、４８．４％ 与良性病变表达率相比差异显著（Ｐ＜ ０．００１），乳腺癌不同组织类型之间无显著差异（Ｐ＞ ０．０５）。核异型性与ＲＰ，ｐ１６ 明显相关（Ｐ＜ ０．０５）；ＥＲ与ｐ１６、肿瘤腺管评分、组织学分级；ＲＰ与ｐ１６；ＡＲ与ｐ５３、患者年龄；ｐ５３ 与核异型性、核分裂相、组织学分级；肿瘤大小与淋巴结转移率分别明显相关。结果表明：ＥＲ、ＰＲ、ＡＲ对患者激素治疗是有价值的指标，ｐ
To evaluate Estrogen Receptor (ER), Progesterone Receptor PR, Androgen Receptor (AR), and Oncogene C-erbB-2Oncoprotein (C-erbB-2) Tum or Suppressor Genes The role of p53 protein (p53) and p16 protein (p16) in the development of breast cancer, and the significance of the above protein detection for diagnosis and treatment. Immunohistochemical S-P method was used to detect the expression of six proteins in 62 cases of breast cancer and 10 cases of benign breast lesions. Results The expression rates of ER, PR, AR, C-erbB-2, p16, p53 in breast cancer were 85.5%, 74.2%, 22.6%, 74.2%, 90.3% respectively. 48.4% was significantly different from the expression rate of benign lesions (P < 0.001), and there was no significant difference between different tissue types of breast cancer (P> 0.05). Nuclear atypia was significantly associated with RP, p16 (P<0.05); ER and p16, tumor duct score, histological grade; RP and p16; AR and p53, patient age; p53 and nuclear atypia, mitotic phase, Histological grade; tumor size and lymph node metastasis were significantly correlated. The results show that ER, PR, and AR are valuable indicators for hormone therapy in patients, p